265 related articles for article (PubMed ID: 20431349)
21. Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer.
Eliyatkin N; Aktas S; Diniz G; Ozgur HH; Ekin ZY; Kupelioglu A
Pathol Oncol Res; 2018 Jan; 24(1):59-65. PubMed ID: 28236153
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Malorni L; Shetty PB; De Angelis C; Hilsenbeck S; Rimawi MF; Elledge R; Osborne CK; De Placido S; Arpino G
Breast Cancer Res Treat; 2012 Dec; 136(3):795-804. PubMed ID: 23124476
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S; Marra A; Gandini S; Ascione L; Ivanova M; Venetis K; Sajjadi E; Zagami P; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Corti C; De Camilli E; Curigliano G; Fusco N; Criscitiello C
Eur J Cancer; 2023 Dec; 195():113397. PubMed ID: 37890353
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
27. Stromal cell expression of caveolin-1 predicts outcome in breast cancer.
Sloan EK; Ciocca DR; Pouliot N; Natoli A; Restall C; Henderson MA; Fanelli MA; Cuello-Carrión FD; Gago FE; Anderson RL
Am J Pathol; 2009 Jun; 174(6):2035-43. PubMed ID: 19411449
[TBL] [Abstract][Full Text] [Related]
28. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast.
Wang J; Zhang X; He J; Yang M; Tang J; Li X; Tang H; Xie X
Med Oncol; 2014 Sep; 31(9):172. PubMed ID: 25119504
[TBL] [Abstract][Full Text] [Related]
30. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.
Witkiewicz AK; Dasgupta A; Nguyen KH; Liu C; Kovatich AJ; Schwartz GF; Pestell RG; Sotgia F; Rui H; Lisanti MP
Cancer Biol Ther; 2009 Jun; 8(11):1071-9. PubMed ID: 19502809
[TBL] [Abstract][Full Text] [Related]
31. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.
Zou M; Li Y; Xia S; Chu Q; Xiao X; Qiu H; Chen Y; Zheng Z; Liu F; Zhuang L; Yu S
Cell Physiol Biochem; 2017; 44(2):778-791. PubMed ID: 29169152
[TBL] [Abstract][Full Text] [Related]
33. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
34. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S129-34. PubMed ID: 21080107
[TBL] [Abstract][Full Text] [Related]
35. MMP-1 expression has an independent prognostic value in breast cancer.
Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients.
Qian N; Ueno T; Kawaguchi-Sakita N; Kawashima M; Yoshida N; Mikami Y; Wakasa T; Shintaku M; Tsuyuki S; Inamoto T; Toi M
Cancer Sci; 2011 Aug; 102(8):1590-6. PubMed ID: 21585620
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
Barbieri V; Sanpaolo P; Genovesi D
Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value Of Basal Markers (Epidermal Growth Factor Receptor "EGFR" And Cytokeratin 5/6) Expression In Triple-Negative Invasive Breast Cancer.
ElFeky AW; Saied EM; Shawky H; Sadaka E
J Pak Med Assoc; 2023 Apr; 73(Suppl 4)(4):S161-S166. PubMed ID: 37482851
[TBL] [Abstract][Full Text] [Related]
40. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA; Elsheikh SE; Aleskandarany MA; Habashi HO; Green AR; Powe DG; El-Sayed ME; Benhasouna A; Brunet JS; Akslen LA; Evans AJ; Blamey R; Reis-Filho JS; Foulkes WD; Ellis IO
Clin Cancer Res; 2009 Apr; 15(7):2302-10. PubMed ID: 19318481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
